Annual report and financial statements for the year ended 31 March 2013
Contents

Chief Executive’s statement 4
Report of the Trustees 6
Independent Auditor’s Report 28
Group Statement of Financial Activities 30
Balance Sheet 31
Cash Flow Statement 32
Notes to the Financial Statements 34
Legal and administrative details 52

Why we’re here
Prostate Cancer UK fights to help more men survive prostate cancer and enjoy a better quality of life.

• We support men living with prostate cancer and prostate disease by providing specialist information and support services.

• We find answers by funding research into causes, tests and treatments.

• We lead change, raising the profile of the disease, campaigning to improve care and creating conversations to spark the right debates, ensuring the cause is on the media and political agendas.

We believe that men deserve better.

Speak to our Specialist Nurses
0800 074 8383*
prostatecanceruk.org

The helpline is open Monday to Friday 9am - 6pm, Wednesday 9am - 8pm
*Calls are recorded for training purposes only.
Confidentiality is maintained between callers and Prostate Cancer UK.
Report of the Council of Management for the year ended 31 March 2013

Total incoming resources

£26.6m (excluding non-recurring income of £2.8 million)

2011/12 2012/13

14% increased expenditure on research, services and awareness

Total expenditure

£20.7m

2011/12

£10.5m

2012/13

£16.6m

£7m increased expenditure on research, services and awareness

2011/12 2012/13

6274 helpline calls Up 15%

39,000 individuals viewing the information pages of our website

Up 58%

560,000 information material distributed
Chief Executive’s statement

We believe men deserve better. It’s that simple. That’s why in the last year we’ve invested £16.6 million in research, services and awareness. It’s why we’ve raised £26.6 million with the help of Movember. It’s the reason we’ve ensured the calls to our helpline are up by 15%, why we’ve distributed over half a million information leaflets and booklets (up 58% from last year), and why we’ve made sure we’ve nearly doubled the number of monthly visitors to the information pages of our website.

Putting men first was why we merged with Prostate Action and why Prostate Cancer UK is now the largest men’s health charity in the UK. It’s why we made working with health professionals a priority, through running educational training to testing new services such as our successful Get Back on Track fatigue programme. It’s the drive behind our continued work to trial new ways of reaching out to men at high risk of developing prostate cancer, particularly African and African Caribbean men. It was the prompt to open five new community support centres across the UK – Manchester, Newcastle, Birmingham, Glasgow and Croydon – to help support men (and their families) living with prostate cancer in their own community. Men are at the centre of everything we do.

We know that when it comes to improving treatments, diagnosis and our knowledge of prostate cancer, research is and always will be the answer. The 17 new pilot awards and project grants (£2.7 million) we funded will help us find these answers. So too will the £800,000 spent on new PhD Studentships and Fellowships, creating the next generation of prostate cancer research experts who will make the future breakthroughs men deserve. With the help of Movember we plan to invest £25 million on research in the next three years.

We’ve forced the conversation back to men’s health. Our award-winning campaign helped reverse the decision on accessing the life-extending drug abiraterone on the NHS, and the Quality Checklist highlighted the inequality of access to good quality care for men in the UK with prostate cancer. The Quality Checklist has been endorsed by 161 MPs and MSPs, The Royal College of General Practitioners, Royal College of Nurses and the British Association of Urological Nurses. We’re not alone in recognising the need to improve access to better care for men in the UK.

But there’s much more to the last year than impressive numbers and statistics. In June we launched our new name and visual identity and followed that up with our MANifesto – a bold statement of intent to find answers, lead change and support men. The Sledgehammer Fund marked our first ever large scale public awareness campaign, raising awareness of us as an organisation and waking up the nation to the reality of prostate cancer.

The last 12 months has been a hugely successful period for Prostate Cancer UK, but each improvement, each new service and every research project we’ve funded has highlighted the need to do more. Working together, we can and will make a brighter future for men in the UK.

Thank you

Owen Sharp
Chief Executive
Working together, we can and will make a brighter future for men in the UK.

Owen Sharp
Chairman’s statement

Men, naturally reticent creatures when it comes to their own health, need a wakeup call. Prostate cancer is set to become the most common cancer by 2030 and already it accounts for over 10,000 men each year. One in eight men will develop it. 250,000 are living with it. Men deserve better.

When I became Chairman of what was then The Prostate Cancer Charity, we employed less than 20 people in one small office. Now, we have over 170 people in seven offices based around the UK and have an annual turnover of nearly £30 million. Today we have a very professional organisation that still retains an innovative and entrepreneurial culture dedicated to helping more men survive prostate cancer. Believe me when I say that Prostate Cancer UK means business.

Thanks to the support of the Movember Foundation, we have committed to spending £25 million on prostate cancer research over the next three years. We have a research strategy that focuses on three key areas for development: identifying men at highest risk of developing prostate cancer; finding better tests to distinguish between aggressive and non-aggressive tumours, and new treatments for advanced prostate cancer. We will make inroads into this disease with the help of our partners and supporters.

That’s not to say we’re ignoring the current generation of men living with this disease or the families who support them, far from it. We’ve also made leaps and bounds in terms of the services we provide for people affected by prostate cancer. We’ve begun reaching out to men in their local community to help with the side effects of treatment through our five new community support centres. We’ve got a team of nurses working at a local level to improve the levels of care men receive through providing direct support and commissioning services from local providers. Our helpline and information provision has never been busier, and our peer to peer support volunteers are continuing to support men with prostate cancer. We’re working to support men now as well as in the future.

I am stepping down as Chairman in October but am happy to report that I will be handing over the Chair to William Russell, who has been a Trustee of Prostate Cancer UK since 2008. William brings over 16 years’ experience of working in the City, 14 with Merrill Lynch. His knowledge, passion and familiarity with the cause will help continue the progress we have made and cement our place as the largest men’s health charity in the UK.

Paul Forster
Chairman
We will make inroads into this disease with the help of our partners and supporters.

Paul Forster
Achievement and performance
Supporting men

Teaming up

In August 2012, Prostate Cancer UK and Prostate Action merged, following a unanimous decision by both their boards. This saw both charities coming together under the banner of Prostate Cancer UK. With the merger, we extended our charitable activities to cover all prostate diseases. This is exciting news as we believe that by working together we can only be stronger, forming a unified force in the fight against prostate cancer and prostate disease. Speaking with a direct, singular voice we will be able to achieve better our aim of giving men’s health the prominence it needs and address the legacy of neglect which surrounds prostate cancer.

By having one organisation and pooling our expertise and remit, we are also making the way clearer for men seeking advice, as well as limiting confusion for those who support and work with both charities. Bringing together our resources will enable us to invest more in ground breaking research, as well as a wider range of services and health professional education.

Improving our services

Last year, thanks to the investment we receive from the Movember Foundation, we embarked on an ambitious programme of growth and improvement in the support we provide to men with prostate cancer and their families.

- The number of calls to our specialist nurse helpline increased by 15% (6274 calls) with a particular jump in the last quarter of the year due to the success of The Sledgehammer Fund, our public awareness campaign which was launched on 1 January 2013.

- Approximately 39,000 individual visitors a month are now viewing the information pages of our website – almost double the number that were visiting when we first re-launched our website in July 2012.

- We distributed 560,000 leaflets and booklets with information to support men and their families through their diagnosis, treatment and through living with prostate cancer, an increase of 58% from 2011/12.

- We also tested new approaches to service provision, in particular “Get Back on Track,” an innovative telephone motivational interviewing programme supporting men to manage and reduce their levels of fatigue – this was very successful and we are now running it as a mainstream service.

Our amazing volunteers

We would like to thank our hugely committed volunteers for the support they give us in providing our services: for example our peer support volunteers who support men directly, and also across the charity in our campaigns, fundraising and awareness raising. By the end of the financial year we had increased our number of volunteers from 380 to over 1000.
Reaching out in the community

In the second half of the year we started our programme to reach men where they live through the provision of community support services. These will help men with the side effects of treatment and, through exercise, lifestyle and counselling interventions, will support men and their families living with prostate cancer.

By the end of the financial year we had opened five community support centres throughout the UK and commissioned services from 12 providers across these areas. We now also have a team of nurses throughout the UK, some employed by Prostate Cancer UK and some working in the NHS and other charities such as hospices, providing support to men and working to improve local services.

We continue to trial new ways to reach high risk groups, particularly men from African and African Caribbean backgrounds. And towards the end of the year we started working with a network of partners across the UK, and in Australia and Canada, in “A Survivorship Action Partnership” to pilot and introduce innovative approaches to help make a step change in the effectiveness of care that men receive. As with all of our work we are involving men living with prostate cancer and other prostate diseases, throughout this process.

Working with health professionals

We invested heavily in our education programme for healthcare professionals, with 623 attendances at courses, 723 at talks and 1322 registrations for e-learning courses, covering all levels of education from increasing GP awareness to advancing specialist knowledge.
An integral part of our mission is to find answers through funding high quality biomedical research. Last year we implemented our new Research Strategy, which has three key priority areas:

- identifying men at high risk of developing prostate cancer
- distinguishing aggressive from non-aggressive cancer
- developing new, targeted treatments for advanced disease.

Our partnership with Movember has helped us increase our research spend and plan for further substantial research investments in the future.
£2.7m → 17 new pilot awards and project grants across the country

£800k → PhD Studentships and Fellowships

£302k → Four additional research projects funded with the merger with Prostate Action

£25m → Next three years planned research investment
Achievement and performance
Leading change

A new identity
With an urgent need to present the charity and the cause to the public in a more direct, more forceful way, we launched a new name and a new visual identity in June 2012. Our new brand has given us the platform we need to tell people about the work we do in a much more compelling way and to be even more distinctive in our aims of helping more men and attracting more funds. We defined, produced and implemented new guidelines for our visual identity, tone of voice, key messages and working principles, working with staff across the charity to begin embedding these throughout our practice and working culture. We publicly launched our new identity and bold ambitions for the future with our MANifesto stakeholder event at the beginning of October 2012.

Campaigning for change
In challenging times for the health sector, Prostate Cancer UK has successfully taken great strides towards delivering lasting changes to men’s experience of care, as well as addressing key injustices in the availability of treatment.

Our campaign to overturn the National Institute for Health and Care Excellence’s decision not to provide the life-extending drug abiraterone for use after chemotherapy was completely successful; men across all nations of the UK should now have access to this drug for use post-chemotherapy. An independent evaluation of the abiraterone campaign highlighted aspects of our work as ‘exemplary’. The campaign was shortlisted for the Scottish Charity Awards in June, and won a prestigious Communique Award for Excellence in Communications (Payers/Policy Makers) in July. The judges praised the charity for an ‘impressive ability to influence the environment and shape outcomes’. The campaign has also been shortlisted for a Charity Times Award in October. It also identified learning which we are applying in subsequent campaign planning. We also launched an internal evaluation champions training and development programme to evaluate better all our work, including our influencing.

Quality Checklist
In response to significant gaps in the standards of care available to men, we developed a comprehensive Quality Checklist for men with prostate cancer. This outlines standards of care that all men should be able to expect, and empowers them to seek the best possible care and support. Endorsements for the checklist were received from the Royal College of General Practitioners, the Royal College of Nurses and the British Association of Urological Nurses, amongst others. We worked with pilot areas to put this resource into use, and discover how best to make these standards a reality for men across the UK. In March 2013 we held campaign days in both Westminster and Holyrood, securing endorsements and action for our Quality Checklist from 161 MPs and MSPs in total, with the help of 38 trained supporter campaigners.

We have also been building our knowledge and understanding of men’s experiences, to inform better our work. We undertook large scale evidence-gathering projects on benign prostate disease and Scottish men’s experiences of care. Finally, in March, we held the first Policy and Campaigns Forum for the charity, involving people affected by prostate cancer directly in decision-making about our future influencing priorities.
The Sledgehammer Fund
On 1 January we launched The Sledgehammer Fund. Preceded by communications with influencers and opinion formers, including senior health professionals and policy makers, this was our first large scale, public awareness, TV advertising campaign, which ran to 31 March 2013. This mass-market media campaign was integrated with social media and fronted by much loved British comedian Bill Bailey. It was devised to ‘rattle the cage’ and stimulate consideration, conversation and donations and increased our prompted brand awareness from 26% to 29%, up by 11.5% (46% amongst those who recognized our advertisements).

• There was a significant increase in public interest in the issue – for example a 71% increased interest in how to check for prostate cancer and a 196% increased interest in the symptoms of the disease.

• It raised the number of calls to our helpline from the same quarter of the previous year by 33%, increased the number of visitors to the website by 99% and the number of publications downloads by 59%

• The total number of publications orders by increased by 64% - 252 of these (consisting of 25,000 materials) distributed as a result of a direct marketing initiative with an audience group of 39,000 health professionals across the UK.

Visitors to the website up by 99%
Number of publication downloads up by 59%
Total number of publications up by 64%
Achievement and performance
Fundraising

The tough economic conditions have been affecting businesses and charities alike. While we remain as vigilant as ever about the unfavourable conditions in which we seek to generate funds, Prostate Cancer UK has had a strong performance in the last 12 months. Gross income (excluding non-recurring income of £4 million) has risen from £23.3 million to £26.6 million which represents a growth of 14%.

We see this growth as a result of a number of factors, but a ‘coming of age’ for men’s health would be the headline reason we would attach to our success. There is increased awareness of the brutal impact of prostate cancer and how it is as big an issue for men as breast cancer is for women. As more and more people come to understand this the willingness to support us through donations has increased. As an organisation we believe men deserve better when it comes to supporting the fight against prostate cancer, and the British public is starting truly to share this belief and express it through donations.

Movember
The largest proportion of our funds continues to come from the high-profile Movember campaign that sees men grow a moustache for a month and raise money from family and friends. Over 350,000 people took part in the Movember 2012 campaign and, as the prime beneficiary in the UK, we will receive £16.8 million. The participation level had increased by approximately 100,000 from the year before, which is an amazing rate of growth. In addition to the funds raised, the Movember campaign is acting as a fantastic way of bringing the importance of men’s health to a national level. The knock-on from this is that more companies, community groups and individuals are keen to support the cause at other times of the year too.

Corporate partners
The last 12 months has seen a very strong performance from a number of income streams. Notably the support from leading companies has been very strong, including our longstanding supporters at Marks & Spencer and Keyline Builders Merchants. We were also delighted and proud to become the chosen charity of Royal Mail for a two-year term, as well as becoming the charity that Carlsberg’s employees have chosen to raise funds for.

Challenge events
In common with other charities, we have seen strong growth in our challenge events programme. This is, in part, because the demand for places in marathon and other events is on the rise due to increased health consciousness in the UK. And we would also attribute some of the growth we have experienced to the inspiration that the London Olympic Games created. Being the Official Charity Partner of the 2012 Virgin London Marathon in such a unique sporting year for the UK was particularly special. The marathon partnership was a shared opportunity with Breast Cancer Care and it raised in excess of £1.2 million for the two charities. The growth in running, and especially cycling, event income is expected to continue into 2013/14 and beyond.
A season saving men’s lives

We were very proud to be the Official Charity Partner of The Football League for the 2012/13 season. Total funds raised via the 72 clubs was over £200,000, with clubs raising £40,000 through collections alone. We also received a one-off donation from Capital One of £50,000. In addition to this we obtained match day inventory worth £70,000 across Football League clubs and recruited 700 new volunteers and the access this gave us to millions of men was invaluable too. As part of The Sledgehammer Fund, we ran some football-themed TV ads on channels such as Sky Sports to help use the passion for the ‘national obsession’ to further our awareness work.

The digital strategy aligned with this activity reached over 1.5 million people on Twitter and accounted for 15% of overall web traffic to our website.

We see male “passion points,” especially sports like football, as a key way of transforming public consciousness of a disease that is tragically killing one man every hour. We are delighted to have secured a commercial agreement to remain as the Official Charity Partner of The Football League for the next three years. This has been agreed as a long-term partnership because of the quality of the fit and the potential impact that can be achieved.

Other donations

We are very grateful to the many thousands of individuals who have supported us through regular donations during the last 12 months. Our legacy and In Memory income continues to be solid, as the harsh impact of prostate cancer leads to families wishing to make a lasting donation to fund our fight, especially after seeing first-hand its impact on taking away a loved one. A special mention should go to the trusts and foundations who have the vision and belief of some of our new and less proven initiatives, specifically Mike Gooley Trailfinders’ Charity for their exceptional gift this year, and for their ongoing support. Support from trusts, high net worth individuals and community groups continues to grow year on year.

Towards the end of the financial year we saw income in excess of £150,000 generated off the back of our Sledgehammer Fund national advertising campaign. Future campaigns will seek to build further the awareness and support for our efforts to crack the most common cancer in men. The campaign gave us an opportunity to experiment with new forms of digital giving which we will be able to build on in future years. Overall, we are confident that we can continue to grow and we would like to offer a very sincere and heartfelt ‘thank you’ to everyone, including all the MoBro’s, who helped support us over the course of the last year.
Financial review

In 2012/13 total incoming resources were £26.6 million, (excluding non-recurring income of £2.8 million), which represented an increase of 14% on the prior year. This was against a decline in income throughout the charity sector of 22%. This continued the strong growth trend of recent years which is the result of the spectacular growth of income from the Movember campaign, and a strong performance across the majority of the charity’s other income streams.

Total expenditure rose from £10.5 million to £20.7 million. This is largely due to the increased expenditure on research, services and awareness from £7.0 million in 2011/12 to £16.6 million in 2012/13. This significant growth will continue in 2013/14.

The charity also operates a wholly-owned subsidiary trading company, Prostate Cancer Trading Ltd, which produced a net profit of £9,000. This will be donated to the charity.
Plans for the future

Services for men
This year will be the second year of our ambitious expansion plans for our support services to men and our goal is significant growth across all areas. In particular:

- we will encourage more men to use our helpline and information resources, aiming for awareness and use to be spread across the UK rather than mainly focused in the south east of England
- we want to establish and grow services in our existing community support centres, and plan to open four new centres during the year, starting with one in Wales in July 2013
- we plan to fund more specialist nurse roles throughout the UK with the support of Movember and the Royal Mail and we will continue to grow our education and volunteering programmes, ensuring a fully UK-wide focus to all our activities
- we will build on the foundations we laid in the previous year by creating and implementing communications strategies aimed at social care professionals across the UK, who can help us to sign-post their patients to our services
- The Survivorship Action Partnership will take a big step forward in October 2013 when we aim to commit funding to major programmes of service improvement working with NHS and other partners.

Raising awareness
During 2013/14 we will try new approaches to raising awareness and encouraging appropriate testing for men at higher risk of prostate cancer. In particular we delivered a high profile event at the Oval in June 2013 to start a new partnership raising the profile of prostate cancer in African and African Caribbean communities.

In terms of brand salience and awareness, we plan to build on the success of The Sledgehammer Fund with another mass-market awareness and fundraising campaign during the same quarter: 1 January – 31 March 2014.

Prior to this, we activated a big push of media and communications activity around Father’s Day 2013 to generate awareness of the issues, influencing men to take responsibility for their health and appealing to their partners to support them to do so.

In the second year of our renewed three year partnership with The Football League we will continue to raise the issue of prostate cancer amongst football fans, staff and the media, raising the profile of our services and establishing Prostate Cancer UK as the football charity throughout the football season, which commences in August 2013.

In the second year of a new brand, we will continuing to engage staff to ensure that our brand values and working principles are understood, embedded and upheld in order to reach our ambitions of reaching many thousands more men who need and deserve high quality support in their experience with prostate cancer.

Our goal
Significant growth across all areas of support services for men

We will try new approaches to raising awareness and encouraging appropriate testing for men at higher risk of prostate cancer
Plans for the future

Research
The Movember Centre of Excellence for prostate cancer research will be our first major strategic award, bringing together leading researchers to tackle the most pressing issues in prostate cancer research. We will continue to underpin excellent prostate cancer research through our pilot and project grant awards whilst ensuring a strong future for prostate cancer research through a vibrant PhD studentship and Fellowship programme. We aim to launch at least one further funding call in a specific topic to ensure that we are able to address all three key areas outlined in our Research Strategy.

Quality Checklist
We will be implementing the Quality Checklist across four pilot areas of the UK – Lambeth in London, Glasgow, Birmingham and Manchester – to demonstrate how these standards can be implemented within the NHS, and improve the quality of men’s care and support.

- We will undertake multiple evidence gathering projects to understand better the needs of men, and identify answers to ongoing difficulties.
- We plan to use the research conducted on benign prostate disease as a starting point to identify better the needs of men with prostatitis and BPH (benign prostate hyperplasia) and continue to campaign for better patient involvement in the Westminster Government’s new Value Based Pricing system for medications provided by the NHS. We do this to ensure the views of men with prostate cancer are included in the new arrangements. We will continue to engage with NICE and the Scottish Medical Council on the appraisal of new drugs including abiraterone for use pre-chemotherapy, Radium-223 and Enzalutamide.

Risk assessment
The major risks to which the charity is exposed, as identified by the Trustees, have been reviewed and systems have been established to mitigate these risks.

A risk register seeks to identify all key risks facing the charity, graded according to their likelihood and impact and identifies mitigating actions to manage them. The register is regularly reviewed and updated by risk owners, the Executive Team and the Audit and Risk Management Committee. Any ‘red light’ issues are brought to each meeting of the Board of Trustees.

Some of the significant risks facing the charity, and actions taken to manage them, are as follows:

- Research grants are reviewed annually, enabling any risk to be identified at an early stage. We only awards grants after a thorough peer-review assessment process.
- Movember continues to provide a large proportion of the charity’s income. We seek to manage the risk involved in such a key funding relationship by taking a prudent approach to increasing its cost base, such as staff headcount, as well as seeking to increase materially other sources of income over the next three years.
• A three-year business and financial plan and annual budget are approved by Trustees. The annual budget forms the basis for financial monitoring. Re-forecasting of financial performance takes place three times a year, enabling any emerging difficulties to be identified early and effectively managed. Financial review is undertaken by the Finance and General Purposes Committee on behalf of the Board, but the Board itself also receives reports on financial performance. The Executive Team of Directors regularly monitors financial performance and delivery.

Public benefit

We have considered the Charity Commission’s guidance on public benefit when reviewing our aims and objectives and in planning future activities.

The public benefit of the charity is in mitigating the effect of prostate cancer and prostate disease in the United Kingdom. Our strategic aims set out below and all of the charity’s activities are designed to achieve this benefit.

The beneficiaries of our work are men and their families - reached either directly or through healthcare professionals. Those who have benefited from our services are detailed in the review of activities. Our service is open to all men in the United Kingdom and their families, without charge.

As a result of the above, the Trustees consider that Prostate Cancer UK clearly satisfies the public benefit test.

Objectives and activities

The charity’s objectives, set out in its Memorandum and Articles of Association, are
• to invest in prostate cancer research and to publish useful results
• to provide information and support to men and their families affected by prostate cancer
• to raise public awareness of prostate cancer and other prostate diseases and their symptoms.
The Members of the Council of Management (‘The Trustees’) of Prostate Cancer UK (‘the charity’), who are also Directors of the charity for the purposes of the Companies Act, submit their annual report and the audited financial statements for the year ended 31 March 2013.

The charity is a charitable company limited by guarantee and was set up on 14 October 1991. This report provides information on the charity’s activity and financial performance from April 2012 to March 2013.

**Governance and management**

Overall strategy and policy for the charity are agreed by the Council of Management (known as the ‘Board of Trustees’), advised by the Chief Executive and Executive Directors who attend all meetings.

At the first meeting of the Trustees each year, one third of the members of the Council retire from office and new elections are held. Following a period of office, a member of the Council is eligible for re-election.

Officers of the Board (Chairman, Treasurer and Vice Chairman) are elected for an initial term of three years. They are then eligible for election for a further, final term of three years. These terms are extendable, exceptionally, at the discretion of the Board of Trustees.
Trustees are generally recruited by open advertisement to ensure the widest field of applicants. A number of the Trustees have been personally affected by prostate cancer. During the year, five Trustees resigned and six were appointed.

New Trustees undertake an induction programme, meeting with staff from across the charity and are provided with relevant background briefing information.

Trustees periodically review governance arrangements to ensure that appropriate structures and mechanisms are in place as the charity evolves.

Additionally, the Research Advisory Committee advises the Board on research investment. Terms of reference for committees are regularly reviewed.

Trustees met on 17 occasions during the year (either as a full Board or in the committees) to review strategy, policy and performance and to set the operating plans and budgets.
Structure

Sub-committees of the Board:

Finance and General Purposes Committee
- reviews in-depth budget and financial plans
- monitors the charity’s financial performance
- makes recommendations to the Board on financial policy matters (e.g. Treasury Management and Reserves)
- scrutinises support services and undertakes any other work delegated to it by the Board.

Nominations and Human Resources Committee
- reviews strategic HR issues and recommends to the Board the reward arrangements and appointment of new Trustees, Officers and the Chief Executive.

Audit and Risk Management Committee
- leads on external audit matters
- responsible for reviewing arrangements for the management of risk.

Services Committee
- provides strategic attention to the development of the charity’s “front line” service provision to men affected by prostate cancer and prostate disease.
The senior management team of the charity during the year was as follows:

Owen Sharp
Chief Executive

Richard Whitley
Director of Resources and Company Secretary

Mark Bishop
Director of Fundraising

Seamus O’Farrell
Director of Communications

Graham Duncan
Interim Director of Operations

Iain Frame
Director of Research

Heather Blake
Director of Services

Sarah Cant
Director of Policy & Strategy

(appointed January 2013)

(appointed March 2013)

(resigned September 2012)

(appointed November 2012)
Structure

Staff

At the time of signing, the staff team comprised 170 employees, based in offices in Hammersmith, west London; Glasgow; Birmingham; Newcastle; Stockport and Croydon.
The charity is organised into seven directorates:

- **Chief Executive**
  responsible for operational leadership of the organisation

- **Fundraising**
  responsible for all fundraising activity and for events management

- **Services**
  responsible for all ‘front line’ services, including Helpline, community services, information, volunteering and support to healthcare professionals

- **Research**
  responsible for research management and delivery of the research strategy 2012 to 2020

- **Policy and Strategy**
  responsible for our policy and influencing agenda, strategic development, gathering evidence, campaigning, and evaluating our impact

- **Communications**
  responsible for all media and public relations, marketing communications, advertising campaigns and brand management

- **Resources**
  responsible for financial management, planning, knowledge management, human resources, database, ICT, governance and facilities management across all of the charity’s offices
Reserves policy

Our reserves policy states that:

“The purpose of free reserves is to ensure uninterrupted services and delivery of the charity’s objectives regardless of short to medium term fluctuations in patterns of income and expenditure or unforeseen financial burdens. Readily available, free reserves to the value of between three and six months’ of the higher of forward-looking income or expenditure, is required to achieve this. The free reserves requirement will be calculated on a quarterly basis and monitored on a monthly basis. Excess reserves (i.e. above the upper level of the target range) may be used to fund increases in expenditure in order to achieve the charity’s objectives subject to agreement by the Board of Trustees. This policy will be reviewed annually as part of the charity’s budgetary processes.

The level of free reserves at the balance sheet date in March 2013 was £8.5 million, compared to £8.3 million in 2011/12. This represents about six months of expenditure at 2013/14 levels and is in line with our policy.

The charity has restricted reserves of £24.1 million at year end. Of this, £23.2 million relates to Movember. The charity accrued income of £16.8 million, £15 million relating to the Movember 2012 and £1.8 million from Movember 2011. The Movember funds will be fully committed to spending across all areas of survivorship, services and research.

Responsibilities of the trustees

Company law requires the Trustees to prepare financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law) which give a true and fair view of the state of affairs of the group and the charity at the end of the financial year and of the Group’s surplus or deficit for the financial year. In doing so the Trustees are required to:

- select suitable accounting policies and then apply them consistently
- make judgements and estimates that are reasonable and prudent
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for maintaining proper and adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. The Trustees are also responsible for safeguarding the assets of the charity and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The Trustees confirm that the audited report and financial statements for Prostate Cancer UK comply with the provisions of the Statement of Recommended Practice (SORP), ‘Accounting and Reporting by Charities’, issued in March 2005, the Companies Act 2006 and the Charity’s Memorandum and Articles of Association.

**Statement of disclosures to auditors:**

(a) So far as the Trustees are aware, there is no relevant audit information of which the charity’s auditors are unaware, and

(b) They have taken all the steps they ought to have taken as Trustees in order to make themselves aware of any relevant audit information and to establish that the charity’s auditors are aware of that information.

**Trustees and directors**

The Trustees and Directors who served the charity during the year were:

Professor Jonathan Waxman (President)
Professor Paul Forster (Chairman)
Ray Kelly (Vice Chair)
Hugh Richardson (Treasurer)
Professor Hing Leung
Dr Timothy Walker CB
William Russell
Dr Mark Britnell
Vanessa Vallely
Sharon Thorne
Robert Humphreys
Professor Roger Kirby (appointed August 2012)
Christopher Smith (appointed August 2012)
Dr Christopher Adams (appointed August 2012)
Ted Clucas (appointed August 2012, resigned December 2012)
Laurance Racke (appointed August 2012)
David A Pretty CBE (appointed August 2012)
Andrew Blessley (resigned July 2012)
Ian Chate (resigned July 2012)
Sue Sayer OBE (resigned December 2012)
John Anderson (resigned December 2012).

**Auditors**

MacIntyre Hudson MHA was appointed as the charity’s auditor at the Annual General Meeting held on 19 July 2007. A special resolution was passed on 10 November 2008 authorising the Directors of the Company to fix the remuneration of the Company’s auditors from 2009/10 onwards.

This report was approved by the Council of Management (Board of Trustees) on 18 July 2013 and authorised to be signed on its behalf by:

Professor Paul Forster
Chairman
18 July 2013
Independent auditor’s report
to the members of Prostate Cancer UK

We have audited the financial statements of Prostate Cancer UK for the year ended 31 March 2013 which comprise the Group Statement of Financial Activities, the Group Income and Expenditure Account, the Group and Parent Charity Balance Sheets, Group Cash Flow Statements and related notes 1 to 26. The financial reporting framework that has been applied to their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and to the charitable company’s trustees, as a body, in accordance with section 44(1) (c) of the Trustee Investment (Scotland) Act 2005 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006 (as amended). Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company’s members, as a body and its trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of trustees and auditor

As explained more fully in the Trustees’ Responsibilities Statement set out on page 11, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report to you in accordance with regulations made under those Acts.

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board’s (APB’s) Ethical Standards for Auditors.

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the charitable company’s circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the trustees; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Annual Report of the Council Management to identify material inconsistencies with the audited financial statements. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.
Independent Auditor’s Report

Opinion on financial statements

In our opinion the financial statements:
• give a true and fair view of the state of the group and charitable company’s affairs as at 31 March 2013 and of the group’s incoming resources and application of resources, including its income and expenditure, for the year then ended;
• have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
• have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Opinion on other matter prescribed by the Companies Act 2006

In our opinion the information given in the Annual Report of the Council of Management for the financial year for which the financial statements are prepared is consistent with the financial statements.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) requires us to report to you if, in our opinion:
• the parent charitable company has not kept proper and adequate accounting records or returns adequate for our audit have not been received from branches not visited by us; or
• the parent company’s financial statements are not in agreement with the accounting records and returns; or
• certain disclosures of trustees’ remuneration specified by law are not made; or
• we have not received all the information and explanations we require for our audit.

Peter Gotham FCA
(Partner)
FOR AND ON BEHALF OF MHA MACINTYRE HUDSON
Chartered Accountants & Statutory Auditor
New Bridge Street House
30-34 New Bridge Street
London
EC4V 6BJ

19 July 2013

MHA Macintyre Hudson is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.
## Prostate Cancer UK

**Group Statement of Financial Activities**

for the year ended 31 March 2013

<table>
<thead>
<tr>
<th>Notes</th>
<th>Unrestricted Funds (£'000)</th>
<th>Restricted Funds (£'000)</th>
<th>Total 2013 (£'000)</th>
<th>Total 2012 (£'000)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Incoming Resources

**Incoming resources from generated funds**

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Voluntary income</td>
<td>3,4</td>
<td>8,131</td>
<td>18,327</td>
<td>26,458</td>
</tr>
<tr>
<td>Interest &amp; investment income</td>
<td>5</td>
<td>135</td>
<td>-</td>
<td>135</td>
</tr>
<tr>
<td>Donation from Prostate Action on merger</td>
<td>6</td>
<td>2,263</td>
<td>118</td>
<td>2,381</td>
</tr>
<tr>
<td><strong>Total Incoming resources from generated funds</strong></td>
<td><strong>10,529</strong></td>
<td><strong>18,445</strong></td>
<td><strong>28,974</strong></td>
<td><strong>23,330</strong></td>
</tr>
<tr>
<td>Other incoming resources</td>
<td>7</td>
<td>403</td>
<td>-</td>
<td>403</td>
</tr>
<tr>
<td><strong>Total incoming resources</strong></td>
<td><strong>10,932</strong></td>
<td><strong>18,445</strong></td>
<td><strong>29,377</strong></td>
<td><strong>23,330</strong></td>
</tr>
</tbody>
</table>

### Resources Expended

**Costs of generating funds:**

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Costs of generating voluntary income</td>
<td>3,4</td>
<td>3,929</td>
<td>-</td>
<td>3,929</td>
</tr>
<tr>
<td>Charitable activities</td>
<td>8</td>
<td>6,691</td>
<td>9,868</td>
<td>16,559</td>
</tr>
<tr>
<td>Governance costs</td>
<td>10</td>
<td>206</td>
<td>-</td>
<td>206</td>
</tr>
<tr>
<td><strong>Total resources expended</strong></td>
<td><strong>10,826</strong></td>
<td><strong>9,868</strong></td>
<td><strong>20,694</strong></td>
<td><strong>10,451</strong></td>
</tr>
</tbody>
</table>

Net incoming resources before other recognised gains/losses

106           8,577     8,683     12,879

### Other recognised gains and losses

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Realised gain on sale of investment assets</td>
<td>15</td>
<td>29</td>
<td>-</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net movement in funds</td>
<td>135</td>
<td>8,577</td>
<td>8,712</td>
<td>12,893</td>
</tr>
<tr>
<td><strong>Total funds brought forward</strong></td>
<td><strong>9,019</strong></td>
<td><strong>15,515</strong></td>
<td><strong>24,534</strong></td>
<td><strong>11,641</strong></td>
</tr>
</tbody>
</table>

**Total funds carried forward**

9,154     24,092     33,246     24,534

A separate statement of financial activities for the charity has not been published by virtue of section 408 of the Companies Act 2006. The charity-only version is also not materially different to that of the Group.

The unconsolidated, charity only, surplus for the year, was £6,322,000
## Prostate Cancer UK
### Balance sheets
#### as at 31 March 2013

<table>
<thead>
<tr>
<th></th>
<th>Group 2013 £'000</th>
<th>Group 2012 £'000</th>
<th>Charity 2013 £'000</th>
<th>Charity 2012 £'000</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fixed assets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tangible fixed assets</td>
<td>368</td>
<td>250</td>
<td>368</td>
<td>250</td>
</tr>
<tr>
<td><strong>Current assets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asset held for resale</td>
<td>619</td>
<td>-</td>
<td>619</td>
<td>-</td>
</tr>
<tr>
<td>Debtors</td>
<td>18,413</td>
<td>16,997</td>
<td>18,466</td>
<td>17,085</td>
</tr>
<tr>
<td>Investments</td>
<td>1</td>
<td>18</td>
<td>1</td>
<td>18</td>
</tr>
<tr>
<td>Cash and short term deposits</td>
<td>24,049</td>
<td>12,321</td>
<td>23,996</td>
<td>12,258</td>
</tr>
<tr>
<td></td>
<td>43,082</td>
<td>29,336</td>
<td>43,082</td>
<td>29,361</td>
</tr>
<tr>
<td><strong>Creditors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amounts falling due within one year</td>
<td>6,817</td>
<td>3,271</td>
<td>6,817</td>
<td>3,296</td>
</tr>
<tr>
<td><strong>Net current assets/liabilities</strong></td>
<td>36,265</td>
<td>26,065</td>
<td>36,265</td>
<td>26,065</td>
</tr>
<tr>
<td><strong>Total assets less current liabilities</strong></td>
<td>36,633</td>
<td>26,315</td>
<td>36,633</td>
<td>26,315</td>
</tr>
<tr>
<td><strong>Creditors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amounts falling due after more than one year</td>
<td>3,387</td>
<td>1,781</td>
<td>3,387</td>
<td>1,781</td>
</tr>
<tr>
<td><strong>Net assets</strong></td>
<td>33,246</td>
<td>24,534</td>
<td>33,246</td>
<td>24,534</td>
</tr>
<tr>
<td><strong>Unrestricted funds</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General</td>
<td>8,537</td>
<td>8,327</td>
<td>8,537</td>
<td>8,327</td>
</tr>
<tr>
<td>Designated</td>
<td>617</td>
<td>692</td>
<td>617</td>
<td>692</td>
</tr>
<tr>
<td></td>
<td>9,154</td>
<td>9,019</td>
<td>9,154</td>
<td>9,019</td>
</tr>
<tr>
<td><strong>Restricted funds</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Movember</td>
<td>23,163</td>
<td>15,000</td>
<td>23,163</td>
<td>15,000</td>
</tr>
<tr>
<td>Other</td>
<td>929</td>
<td>515</td>
<td>929</td>
<td>515</td>
</tr>
<tr>
<td></td>
<td>24,092</td>
<td>15,515</td>
<td>24,092</td>
<td>15,515</td>
</tr>
<tr>
<td><strong>Total funds</strong></td>
<td>33,246</td>
<td>24,534</td>
<td>33,246</td>
<td>24,534</td>
</tr>
</tbody>
</table>

Approved by the Council of Management on 18 July 2013 and signed on its behalf by: Professor Paul Forster - Chairman
## Prostate Cancer UK

**Group Cash Flow Statement**

for the year ended 31 March 2013

<table>
<thead>
<tr>
<th>Notes</th>
<th>2013 £’000</th>
<th>2012 £’000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net cash inflow/(outflow) from operating activities</td>
<td>25</td>
<td>11,933</td>
</tr>
<tr>
<td>Returns on investments and servicing of finance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest received</td>
<td>5</td>
<td>96</td>
</tr>
<tr>
<td>Dividends received</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>135</td>
</tr>
<tr>
<td>Capital expenditure and financial investment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Payments to acquire tangible fixed assets</td>
<td>(369)</td>
<td></td>
</tr>
<tr>
<td>Sale of Investments</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(340)</td>
<td></td>
</tr>
<tr>
<td>Increase/(Decrease) in cash</td>
<td>11,728</td>
<td></td>
</tr>
<tr>
<td>Net cash resources at 1 April</td>
<td>12,321</td>
<td></td>
</tr>
<tr>
<td>Net cash resources at 31 March</td>
<td></td>
<td>24,049</td>
</tr>
</tbody>
</table>

A separate cash flow statement for the charity has not been published as the charity-only version is not materially different.
They listened, were caring and gave all the information I needed. They helped me get my head together. I had my treatment and I’m still here smiling and enjoying life.

A personal experience
Prostate Cancer UK
Notes forming part of the financial statements
as at 31 March 2013

I Basis of accounting

1.1 The financial statements have been prepared under the historical cost basis of accounting as modified by the revaluation of certain assets and in accordance with United Kingdom Generally Accepted Accounting Practice and the Statement of Recommended Practice: Accounting and Reporting by Charities (SORP 2005). The financial statements consolidate the charity’s individual financial statements with its subsidiary undertaking and dormant entities on a line-by-line basis. No separate company Statement of Financial Activities or Income and Expenditure Account has been presented as permitted by the Companies Act 2006.

2 Accounting policies

2.1 Income is shown gross.

2.2 All income and expenditure is included in these financial statements on a full accruals basis. Donations and legacies are accounted for when the charity is entitled to receipt and the amount can be measured with reasonable certainty. Legacies in the form of property or investments are included at market value.

2.3 Donated services and gifts are included at the estimated value to Prostate Cancer UK. Where possible, this is based on an estimate provided by the donor. In accordance with SORP 2005, no amounts have been included in these financial statements to reflect the value of services provided free of charge to the charity by volunteers.

2.4 Resources expended are recognised in the period in which they are incurred. Resources expended include attributable VAT which cannot be recovered.

2.5 Charitable activities include expenditure associated with research grants, community engagement, Helpline and information services, policy and media and public affairs.

2.6 Grants payable are included in both the Group Statement of Financial Activities and Group Income and Expenditure Account when approved by the Trustees and agreed with the recipient organisation. The value of such grants unpaid at the year end is accrued.

2.7 Costs of generating funds relates to expenditure incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

2.8 Governance costs are those incurred in the governance of the charity and its assets.

2.9 Support costs are allocated between fundraising, charitable activities and governance on the basis of the staff time devoted to, and actual expenditure incurred (including overheads) in, each activity. Cost allocation includes an element of judgement and the charity has had to consider the cost-benefit of detailed calculations and record keeping.

2.10 Rentals payable under operating leases are charged to Group Statement of Financial Activities and Group Income and Expenditure Account as incurred.

2.11 The charity operates defined contribution pension schemes for certain employees. The assets of these schemes are held separately from those of the charity in independently administered funds. Contributions in respect of these schemes are charged against net incoming resources in the year in which they are due.
2.12 Tangible fixed assets and depreciation:
Expenditure on assets over the value of £1,000 is capitalised. Depreciation is provided on a straight line basis at the following annual rates in order to write off each asset over its estimated useful life:
- Lease improvements: 20%
- Computer equipment, software and website redevelopment: 33%
- Fixtures and fittings: 33%

2.13 Investments held as fixed assets are revalued at mid-market value at the balance sheet date. Any gain or loss is taken to the Group Statement of Financial Activities and Group Income and Expenditure Account. The investment in the subsidiary is recognised at cost.

2.14 Fund accounting:
The following funds are held by the charity:
- Unrestricted - these are funds which can be used in accordance with the charitable objects at the discretion of the Council.
- Designated - these are funds set aside by the Council out of unrestricted funds for specific future purposes.
- Restricted - these are funds that can only be used for particular restricted purposes. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

2.15 During the year the charity merged with Prostate Action. This has been accounted for as an acquisition due to the dominant position of the charity in managing the combined entity. The assets and liabilities of Prostate Action have been recognised at fair value as at the date of the merger. The results of the activities acquired are included from the date of the merger.
## Prostate Cancer UK

### Notes forming part of the financial statements as at 31 March 2013

### 3 Voluntary income and costs of generating voluntary income

<table>
<thead>
<tr>
<th>Income</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>£’000</td>
<td>£’000</td>
</tr>
<tr>
<td>Direct marketing</td>
<td>1,697</td>
<td>202</td>
</tr>
<tr>
<td>Community fundraising</td>
<td>1,872</td>
<td>12</td>
</tr>
<tr>
<td>Movember</td>
<td>-</td>
<td>16,800</td>
</tr>
<tr>
<td>Charitable trusts</td>
<td>501</td>
<td>240</td>
</tr>
<tr>
<td>Legacies</td>
<td>1,066</td>
<td>74</td>
</tr>
<tr>
<td>In Memory</td>
<td>340</td>
<td>16</td>
</tr>
<tr>
<td>Corporate donors</td>
<td>772</td>
<td>692</td>
</tr>
<tr>
<td>Challenge events</td>
<td>1,420</td>
<td>2</td>
</tr>
<tr>
<td>Major donors</td>
<td>84</td>
<td>28</td>
</tr>
<tr>
<td>Gala &amp; special events</td>
<td>163</td>
<td>-</td>
</tr>
<tr>
<td>Donated goods and services</td>
<td>59</td>
<td>-</td>
</tr>
<tr>
<td>Other donations</td>
<td>130</td>
<td>36</td>
</tr>
<tr>
<td>Scottish Government Statutory Income</td>
<td>-</td>
<td>225</td>
</tr>
<tr>
<td>Total</td>
<td>8,104</td>
<td>18,327</td>
</tr>
</tbody>
</table>

Income less costs provides the net contribution figures below:

<table>
<thead>
<tr>
<th>Income</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>£’000</td>
<td>£’000</td>
<td></td>
</tr>
<tr>
<td>Direct marketing</td>
<td>540</td>
<td>606</td>
</tr>
<tr>
<td>Community fundraising</td>
<td>1,379</td>
<td>1,286</td>
</tr>
<tr>
<td>Movember</td>
<td>16,800</td>
<td>15,000</td>
</tr>
<tr>
<td>Charitable trusts</td>
<td>612</td>
<td>691</td>
</tr>
<tr>
<td>Legacies</td>
<td>985</td>
<td>464</td>
</tr>
<tr>
<td>In Memory</td>
<td>298</td>
<td>293</td>
</tr>
<tr>
<td>Corporate donors</td>
<td>805</td>
<td>964</td>
</tr>
<tr>
<td>Challenge events</td>
<td>595</td>
<td>585</td>
</tr>
<tr>
<td>Major donors</td>
<td>18</td>
<td>40</td>
</tr>
<tr>
<td>Gala &amp; special events</td>
<td>38</td>
<td>(4)</td>
</tr>
<tr>
<td>Donated goods and services</td>
<td>59</td>
<td>20</td>
</tr>
<tr>
<td>Other donations</td>
<td>166</td>
<td>-</td>
</tr>
<tr>
<td>Scottish Government Statutory Income</td>
<td>225</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>22,520</td>
<td>19,945</td>
</tr>
</tbody>
</table>
### Voluntary income and costs of generating voluntary income

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Direct costs</td>
<td>Support costs</td>
</tr>
<tr>
<td>Direct marketing</td>
<td>1,697</td>
<td>202</td>
</tr>
<tr>
<td>Community fundraising</td>
<td>1,872</td>
<td>12</td>
</tr>
<tr>
<td>Movember</td>
<td>-</td>
<td>16,800</td>
</tr>
<tr>
<td>Charitable trusts</td>
<td>501</td>
<td>240</td>
</tr>
<tr>
<td>Legacies</td>
<td>1,066</td>
<td>74</td>
</tr>
<tr>
<td>In Memory</td>
<td>340</td>
<td>16</td>
</tr>
<tr>
<td>Corporate donors</td>
<td>772</td>
<td>692</td>
</tr>
<tr>
<td>Challenge events</td>
<td>1,420</td>
<td>2</td>
</tr>
<tr>
<td>Major donors</td>
<td>84</td>
<td>28</td>
</tr>
<tr>
<td>Gala &amp; special events</td>
<td>163</td>
<td>-</td>
</tr>
<tr>
<td>Donated goods and services</td>
<td>59</td>
<td>-</td>
</tr>
<tr>
<td>Other donations</td>
<td>130</td>
<td>36</td>
</tr>
<tr>
<td>Scottish Government Statutory Income</td>
<td>-</td>
<td>225</td>
</tr>
</tbody>
</table>

Total income: 23,171, Total costs: 3,226

Movember receives all proceeds and meets the costs of its Campaign. In accordance with a three year contractual arrangement commencing November 2011, the charity is the major beneficiary of their Campaign and each year is entitled to receive the first £15m of net proceeds (dependant upon the success of the campaign) as restricted grant funding and upon successful delivery of programs meeting Movember’s strategic objectives. The funds are payable in equal instalments in May and December of the year following each campaign.
Prostate Cancer UK
Notes forming part of the financial statements
as at 31 March 2013

4 Net income and assets from trading activities of subsidiary
The charity has a wholly-owned subsidiary incorporated in England, Prostate Cancer Trading Limited, which raises funds through trading activity, marketing and the sales of goods. The company pays its profits under Gift Aid to Prostate Cancer UK. Audited accounts will be filed with the Registrar of Companies. A summary of its trading results for the year ended 31 March 2013 is as follows:

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Turnover</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Sales of goods</td>
<td>2</td>
<td>24</td>
</tr>
<tr>
<td>Income from corporate partnerships</td>
<td>25</td>
<td>44</td>
</tr>
<tr>
<td></td>
<td>27</td>
<td>68</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>11</td>
<td>31</td>
</tr>
<tr>
<td>Gross profit</td>
<td>16</td>
<td>37</td>
</tr>
<tr>
<td>Administrative expenses</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>Interest payable</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Net profit</td>
<td>9</td>
<td>25</td>
</tr>
<tr>
<td>Income transferred by Gift Aid</td>
<td>9</td>
<td>25</td>
</tr>
<tr>
<td>Retained in subsidiary</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

In addition, the charity acquired the net assets of Prostate Action, a charity and company registered in England & Wales. Further details of this are given on note 6. Prostate Action operates in the same charitable field as Prostate Cancer UK.
## 5 Interest & other income

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>£’000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dividends received</td>
<td>10</td>
<td>1</td>
</tr>
<tr>
<td>Interest received</td>
<td>96</td>
<td>70</td>
</tr>
<tr>
<td>Other income</td>
<td>29</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td><strong>135</strong></td>
<td><strong>91</strong></td>
</tr>
</tbody>
</table>
Prostate Cancer UK
Notes forming part of the financial statements
as at 31 March 2013

6 Donation from Prostate Action

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donation from Prostate Action on merger</td>
<td>£'000 2,381</td>
</tr>
</tbody>
</table>

At 31 July 2012, Prostate Cancer UK and Prostate Action merged. Following that date the assets and liabilities of Prostate Action were transferred into Prostate Cancer UK and Prostate Action became dormant. This transaction was accounted for using acquisition accounting (see accounting policies).

The amount shown above represents the excess of assets over liabilities at that date which is treated as a donation as there was no consideration given.

The post-acquisition results of the operations transferred from Prostate Action and its contribution towards income and the surplus for the year is as follows:

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contribution to income</td>
<td>£'000 769</td>
</tr>
<tr>
<td>Contribution to surplus</td>
<td>£'000 459</td>
</tr>
</tbody>
</table>

The fair value of the assets and liabilities acquired at 31 July 2012 are as follows:

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Fixed Assets</td>
<td>£'000 686</td>
</tr>
<tr>
<td>Total Investments</td>
<td>£'000 1,501</td>
</tr>
<tr>
<td></td>
<td>£'000 2,187</td>
</tr>
<tr>
<td>Total Debtors</td>
<td>£'000 91</td>
</tr>
<tr>
<td>Total Cash at Bank</td>
<td>£'000 1,007</td>
</tr>
<tr>
<td></td>
<td>£'000 3,285</td>
</tr>
<tr>
<td>Creditors within one year</td>
<td>(£'000 525)</td>
</tr>
<tr>
<td>Creditors after one year</td>
<td>(£'000 379)</td>
</tr>
<tr>
<td></td>
<td>£'000 2,381</td>
</tr>
<tr>
<td>Total Unrestricted Funds</td>
<td>£'000 2,263</td>
</tr>
<tr>
<td>Total Restricted Funds</td>
<td>£'000 118</td>
</tr>
<tr>
<td></td>
<td>£'000 2,381</td>
</tr>
</tbody>
</table>
7 Other incoming resources

<table>
<thead>
<tr>
<th></th>
<th>2013 £'000</th>
<th>2012 £'000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Settlement of claims in connection with a legal dispute, less related costs</td>
<td>1,608</td>
<td>-</td>
</tr>
<tr>
<td>Cost of termination of office leases</td>
<td>(1,205)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>403</td>
<td>-</td>
</tr>
</tbody>
</table>

8 Charitable activities

<table>
<thead>
<tr>
<th></th>
<th>Direct costs £'000</th>
<th>Support costs £'000</th>
<th>Total costs £'000</th>
<th>2013 £'000</th>
<th>2012 £'000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>4,071</td>
<td>981</td>
<td>5,052</td>
<td>624</td>
<td>364</td>
</tr>
<tr>
<td>Services</td>
<td>4,049</td>
<td>970</td>
<td>5,019</td>
<td>1,806</td>
<td>1,205</td>
</tr>
<tr>
<td>Awareness</td>
<td>4,777</td>
<td>910</td>
<td>5,687</td>
<td>3,280</td>
<td>4,071</td>
</tr>
<tr>
<td>Policy and Strategy</td>
<td>646</td>
<td>155</td>
<td>801</td>
<td>1,324</td>
<td>1,205</td>
</tr>
<tr>
<td></td>
<td>13,543</td>
<td>3,016</td>
<td>16,559</td>
<td>7,034</td>
<td>5,074</td>
</tr>
</tbody>
</table>
### 9 Grants awarded

<table>
<thead>
<tr>
<th></th>
<th>2013 £'000</th>
<th>2012 £'000</th>
</tr>
</thead>
<tbody>
<tr>
<td>University of Newcastle</td>
<td>543</td>
<td>-</td>
</tr>
<tr>
<td>University of York</td>
<td>385</td>
<td>-</td>
</tr>
<tr>
<td>King's College London</td>
<td>377</td>
<td>-</td>
</tr>
<tr>
<td>Queen Mary, University of London</td>
<td>374</td>
<td>-</td>
</tr>
<tr>
<td>University of East Anglia</td>
<td>250</td>
<td>-</td>
</tr>
<tr>
<td>University of Strathclyde</td>
<td>249</td>
<td>-</td>
</tr>
<tr>
<td>University of Cardiff</td>
<td>292</td>
<td>-</td>
</tr>
<tr>
<td>University of Dundee</td>
<td>237</td>
<td>-</td>
</tr>
<tr>
<td>University of Ulster</td>
<td>214</td>
<td>-</td>
</tr>
<tr>
<td>University of Glasgow</td>
<td>205</td>
<td>-</td>
</tr>
<tr>
<td>The Institute of Cancer Research</td>
<td>385</td>
<td>-</td>
</tr>
<tr>
<td>University of Southampton</td>
<td>113</td>
<td>-</td>
</tr>
<tr>
<td>Queen's University Belfast</td>
<td>107</td>
<td>-</td>
</tr>
<tr>
<td>Erasmus MC, Netherlands</td>
<td>100</td>
<td>-</td>
</tr>
<tr>
<td>University of Oxford</td>
<td>100</td>
<td>-</td>
</tr>
<tr>
<td>University of Bradford</td>
<td>99</td>
<td>-</td>
</tr>
<tr>
<td>Imperial College London</td>
<td>99</td>
<td>250</td>
</tr>
<tr>
<td>University of Stirling</td>
<td>97</td>
<td>-</td>
</tr>
<tr>
<td>Leiden University, Netherlands</td>
<td>73</td>
<td>-</td>
</tr>
<tr>
<td>University College London</td>
<td>63</td>
<td>-</td>
</tr>
<tr>
<td>University of Sheffield</td>
<td>50</td>
<td>-</td>
</tr>
<tr>
<td>University of Cambridge</td>
<td>49</td>
<td>-</td>
</tr>
<tr>
<td>University of Sunderland</td>
<td>15</td>
<td>-</td>
</tr>
<tr>
<td>University of Leicester</td>
<td>14</td>
<td>-</td>
</tr>
<tr>
<td>Prostate Cancer Support Federation</td>
<td>3</td>
<td>-</td>
</tr>
<tr>
<td>University of Aberystwyth</td>
<td>-</td>
<td>205</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>4,493</td>
<td>455</td>
</tr>
</tbody>
</table>
Support costs associated with grants amounted to £152,295 (£82,331 in 2012).

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2,012</th>
</tr>
</thead>
<tbody>
<tr>
<td>£'000</td>
<td>£'000</td>
<td></td>
</tr>
</tbody>
</table>

Reconciliation of grants payable:

- Commitments at 1 April: 3,184, 5,090
- Commitments made in the year: 4,493, 455
- Grants paid during the year: (1,503), (2,361)

Commitments at 31 March

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>6,174</td>
</tr>
<tr>
<td></td>
<td>3,184</td>
</tr>
</tbody>
</table>

Commitments at 31 March are payable as follows:

- Within one year (note 18): 3,101, 1,680
- After more than one year (note 19): 3,073, 1,504

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>6,174</td>
</tr>
<tr>
<td></td>
<td>3,184</td>
</tr>
</tbody>
</table>
Prostate Cancer UK
Notes forming part of the financial statements
as at 31 March 2013

IO Governance

<table>
<thead>
<tr>
<th></th>
<th>Direct Costs £'000</th>
<th>Support Costs £'000</th>
<th>Total Costs £'000</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Legal and professional fees</td>
<td>43</td>
<td>-</td>
<td>43</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>External audit</td>
<td>30</td>
<td>-</td>
<td>15</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Other fees payable to auditors</td>
<td>2</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Trustee expenses</td>
<td>5</td>
<td>-</td>
<td>5</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Apportionment of staff &amp; support costs</td>
<td>61</td>
<td>65</td>
<td>141</td>
<td>122</td>
<td></td>
</tr>
<tr>
<td></td>
<td>141</td>
<td>65</td>
<td>206</td>
<td>148</td>
<td></td>
</tr>
</tbody>
</table>

II Council of Management and employee information

No member of the Council received any remuneration from the charity. Directly incurred expenses are reimbursed, if claimed. In the year ended 31 March 2013 travelling and other expenses amounting to £5,366 were reimbursed to 2 trustees (2011/12: £6,464 to 2 trustees).

The average full-time equivalent number of persons employed by the charity during the year was:-

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fundraising</td>
<td>33</td>
<td>29</td>
</tr>
<tr>
<td>Research</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Services</td>
<td>45</td>
<td>30</td>
</tr>
<tr>
<td>Policy &amp; Strategy</td>
<td>10</td>
<td>3</td>
</tr>
<tr>
<td>Communications</td>
<td>22</td>
<td>15</td>
</tr>
<tr>
<td>Resources</td>
<td>22</td>
<td>21</td>
</tr>
<tr>
<td>Chief Executive’s Office</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>139</td>
<td>102</td>
</tr>
</tbody>
</table>

Trustee indemnity insurance for the year was set at £2m cover collectively.

Amounts paid to employees by the charity during the year increased by 28% (2011/12: 23%) and were:-

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salaries and wages</td>
<td>5,006</td>
<td>3,799</td>
</tr>
<tr>
<td>National insurance costs</td>
<td>559</td>
<td>423</td>
</tr>
<tr>
<td>Pension costs</td>
<td>150</td>
<td>131</td>
</tr>
<tr>
<td></td>
<td>5,715</td>
<td>4,353</td>
</tr>
</tbody>
</table>
The number of employees of the charity paid within each of the following ranges was:

<table>
<thead>
<tr>
<th>Range</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>£60,001 to £70,000</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>£70,001 to £80,000</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>£80,001 to £90,000</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>£90,001 to £100,000</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>£100,001 to £110,000</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>£110,001 to £120,000</td>
<td>1</td>
<td>-</td>
</tr>
</tbody>
</table>

The charity made pension contributions under a defined contribution scheme amounting to £21,616 (2011/12: £20,151), in respect of seven (2011/12: 5) higher paid employees.

12 Pension costs
The charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in independently administered funds. The pension cost represents contributions paid by the charity to the funds and amounted to £150,007 (2011/12: £130,619). The amount payable at the year end amounted to £29,291 (2011/12: £21,699).

13 Support costs
The breakdown of support costs and how these are allocated are shown below:

<table>
<thead>
<tr>
<th></th>
<th>Cost of generating income</th>
<th>Charitable activities</th>
<th>Governance</th>
<th>Total costs 2013</th>
<th>Total costs 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Staff and similar costs</td>
<td>£559</td>
<td>£1,777</td>
<td>£20</td>
<td>£2,356</td>
<td>£1,908</td>
</tr>
<tr>
<td>Supplies and services</td>
<td>£189</td>
<td>£600</td>
<td>£18</td>
<td>£807</td>
<td>£374</td>
</tr>
<tr>
<td>Premises costs</td>
<td>£145</td>
<td>£454</td>
<td>£25</td>
<td>£624</td>
<td>£531</td>
</tr>
<tr>
<td>Depreciation</td>
<td>£53</td>
<td>£185</td>
<td>£2</td>
<td>£240</td>
<td>£160</td>
</tr>
</tbody>
</table>

|                      | £946                       | £3,016                | £65        | £4,027           | £2,973           |

Cost allocation includes an element of judgement and the charity has had to consider the cost-benefit of detailed calculations and record keeping. Where possible, support costs are charged to a specific activity and the balance has been allocated using the basis of overall full-time equivalent staff numbers.
Prostate Cancer UK
Notes forming part of the financial statements
as at 31 March 2013

14 Tangible fixed assets - group and charity

<table>
<thead>
<tr>
<th></th>
<th>Lease improvements</th>
<th>Fixtures and fittings</th>
<th>Computer equipment/software</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>£'000</td>
<td>£'000</td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Cost</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 1 April 2012</td>
<td>127</td>
<td>193</td>
<td>502</td>
<td>822</td>
</tr>
<tr>
<td>Additions</td>
<td>116</td>
<td>157</td>
<td>99</td>
<td>372</td>
</tr>
<tr>
<td>Disposals</td>
<td></td>
<td>(74)</td>
<td>(8)</td>
<td>(82)</td>
</tr>
<tr>
<td>At 31 March 2013</td>
<td>243</td>
<td>276</td>
<td>593</td>
<td>1,112</td>
</tr>
<tr>
<td>Depreciation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 1 April 2012</td>
<td>100</td>
<td>100</td>
<td>372</td>
<td>572</td>
</tr>
<tr>
<td>Disposals</td>
<td></td>
<td>(60)</td>
<td>(8)</td>
<td>(68)</td>
</tr>
<tr>
<td>Charge for the year</td>
<td>77</td>
<td>68</td>
<td>95</td>
<td>240</td>
</tr>
<tr>
<td>At 31 March 2013</td>
<td>177</td>
<td>108</td>
<td>459</td>
<td>744</td>
</tr>
<tr>
<td>Net book value</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net book value at 31 March 2013</td>
<td>66</td>
<td>168</td>
<td>134</td>
<td>368</td>
</tr>
<tr>
<td>Net book value at 31 March 2012</td>
<td>27</td>
<td>93</td>
<td>130</td>
<td>250</td>
</tr>
</tbody>
</table>

On the basis that it is the intention to exit the lease at Cambridge House, depreciation of the lease improvements has been accelerated and is not in line with the accounting policy of 20% straight line method.

15 Investments - group and charity

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Market value:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 1 April</td>
<td>18</td>
<td>82</td>
</tr>
<tr>
<td>Additions on merger</td>
<td>1,501</td>
<td>-</td>
</tr>
<tr>
<td>Disposals</td>
<td>(1,547)</td>
<td>(78)</td>
</tr>
<tr>
<td>Realised gains</td>
<td>29</td>
<td>14</td>
</tr>
<tr>
<td>At 31 March</td>
<td>1</td>
<td>18</td>
</tr>
<tr>
<td>Historical cost as at 31 March</td>
<td>1</td>
<td>18</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>UK listed investments:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>1</td>
<td>18</td>
</tr>
</tbody>
</table>

The charity’s investment in its subsidiary undertaking amounted to £100 representing 100 ordinary shares, representing the entire share capital of the subsidiary.
I6 Asset held for resale

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Freehold Property</td>
<td>619</td>
<td>-</td>
</tr>
</tbody>
</table>

The freehold property comprises offices owned and used by the charity following the merger with Prostate Action during the year. The above amount is expected net sales proceeds of the property which is currently being marketed.

I7 Debtors

<table>
<thead>
<tr>
<th></th>
<th>Group</th>
<th>Charity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2013</td>
<td>2012</td>
</tr>
<tr>
<td></td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Legacies</td>
<td>112</td>
<td>322</td>
</tr>
<tr>
<td>Tax recoverable</td>
<td>177</td>
<td>378</td>
</tr>
<tr>
<td>Subsidiary company</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Prepayments</td>
<td>347</td>
<td>437</td>
</tr>
<tr>
<td>Other debtors</td>
<td>977</td>
<td>860</td>
</tr>
<tr>
<td></td>
<td>1,613</td>
<td>1,997</td>
</tr>
<tr>
<td>Movember accrued income</td>
<td>16,800</td>
<td>15,000</td>
</tr>
<tr>
<td></td>
<td>18,413</td>
<td>16,997</td>
</tr>
</tbody>
</table>

Movember income is paid in two equal instalments in May and December of the following year. Movember also committed a further £1.8m in 2013 for the ASAP (A Survivorship Action Plan) programme.

There is no specific security or repayment terms in respect of the loan to the subsidiary company. No interest was charged on this amount. An interest bearing current account operates between the trading company and Prostate Cancer UK, to assist with the cash flow requirements of the subsidiary during any accounting period.

I8 Creditors - falling due within one year

<table>
<thead>
<tr>
<th></th>
<th>Group</th>
<th>Charity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2013</td>
<td>2012</td>
</tr>
<tr>
<td></td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td>Trade creditors</td>
<td>1,481</td>
<td>1,175</td>
</tr>
<tr>
<td>Research commitments</td>
<td>3,101</td>
<td>1,680</td>
</tr>
<tr>
<td>Other taxes and social security</td>
<td>176</td>
<td>106</td>
</tr>
<tr>
<td>Accruals</td>
<td>602</td>
<td>286</td>
</tr>
<tr>
<td>Creditors</td>
<td>1,457</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>6,817</td>
<td>3,271</td>
</tr>
</tbody>
</table>

Deferred voluntary income relating to activities taking place after the year end included in the above amounted to £229,417 (2012: £285,920).
Prostate Cancer UK
Notes forming part of the financial statements
as at 31 March 2013

19 Creditors - falling due after more than one year

<table>
<thead>
<tr>
<th></th>
<th>Group 2013</th>
<th>Group 2012</th>
<th>Charity 2013</th>
<th>Charity 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research commitments</td>
<td>3,073</td>
<td>1,504</td>
<td>3,073</td>
<td>1,504</td>
</tr>
<tr>
<td>Dilapidations provision</td>
<td>-</td>
<td>277</td>
<td>-</td>
<td>277</td>
</tr>
<tr>
<td>Programme commitments~</td>
<td>314</td>
<td>-</td>
<td>314</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>3,387</td>
<td>1,781</td>
<td>3,387</td>
<td>1,781</td>
</tr>
</tbody>
</table>

Programme commitments comprise funding to Urological Cancers (UCAN) and The Royal Marsden Hospital for two part time nurses over three years and two full-time nurses over two years, respectively. No restrictive performance conditions are placed on these grants.

20 Analysis of net assets between funds

<table>
<thead>
<tr>
<th></th>
<th>General funds</th>
<th>Designated funds</th>
<th>Restricted funds</th>
<th>Total funds</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>£’000</td>
<td>£’000</td>
<td>£’000</td>
<td>£’000</td>
</tr>
<tr>
<td>Tangible fixed assets (note 14)</td>
<td>-</td>
<td>368</td>
<td>-</td>
<td>368</td>
</tr>
<tr>
<td>Investments</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Current assets less liabilities</td>
<td>8,536</td>
<td>249</td>
<td>24,092</td>
<td>32,877</td>
</tr>
<tr>
<td>Net assets at 31 March 2013</td>
<td>8,537</td>
<td>617</td>
<td>24,092</td>
<td>33,246</td>
</tr>
</tbody>
</table>
## Movement in funds

<table>
<thead>
<tr>
<th></th>
<th>As at 1.4.2012</th>
<th>Incoming</th>
<th>Outgoing</th>
<th>As at 31.3.2013</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Restricted funds</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Movember-Research</td>
<td>£7,500</td>
<td>£9,300</td>
<td>£3,687</td>
<td>£13,113</td>
</tr>
<tr>
<td>Movember-Survivorship</td>
<td>£7,500</td>
<td>£7,500</td>
<td>(4,950)</td>
<td>£10,050</td>
</tr>
<tr>
<td><strong>Movember</strong></td>
<td>£15,000</td>
<td>£16,800</td>
<td>(8,637)</td>
<td>£23,163</td>
</tr>
<tr>
<td><strong>Other restricted funds:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- General research</td>
<td>£490</td>
<td>£118</td>
<td>(283)</td>
<td>£325</td>
</tr>
<tr>
<td>- Research nurse</td>
<td>£1</td>
<td>-</td>
<td>(1)</td>
<td>-</td>
</tr>
<tr>
<td>Royal Mail</td>
<td>-</td>
<td>£506</td>
<td>(127)</td>
<td>£379</td>
</tr>
<tr>
<td>Marks &amp; Spencer PLC</td>
<td>-</td>
<td>£119</td>
<td>(119)</td>
<td>-</td>
</tr>
<tr>
<td>Scotland development - The Big Lottery Fund</td>
<td>£5</td>
<td>-</td>
<td>(5)</td>
<td>-</td>
</tr>
<tr>
<td>African-Caribbean projects</td>
<td>£2</td>
<td>-</td>
<td>(2)</td>
<td>-</td>
</tr>
<tr>
<td>Masterclasses</td>
<td>£9</td>
<td>-</td>
<td>(9)</td>
<td>-</td>
</tr>
<tr>
<td>Older and Wiser</td>
<td>£3</td>
<td>-</td>
<td>(3)</td>
<td>-</td>
</tr>
<tr>
<td>National Cancer Survivorship Initiative</td>
<td>£5</td>
<td>-</td>
<td>(5)</td>
<td>-</td>
</tr>
<tr>
<td>Statutory income</td>
<td>-</td>
<td>£225</td>
<td>-</td>
<td>£225</td>
</tr>
<tr>
<td>Other Restricted funds</td>
<td>-</td>
<td>£677</td>
<td>(677)</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total restricted funds</strong></td>
<td>£515</td>
<td>£1,645</td>
<td>(1,231)</td>
<td>£929</td>
</tr>
<tr>
<td><strong>Total restricted funds</strong></td>
<td>£15,515</td>
<td>£18,445</td>
<td>(9,868)</td>
<td>£24,092</td>
</tr>
<tr>
<td><strong>General fund</strong></td>
<td>£8,050</td>
<td>£12,107</td>
<td>(11,620)</td>
<td>£8,537</td>
</tr>
<tr>
<td><strong>Designated funds</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fixed asset reserves fund</td>
<td>£542</td>
<td>-</td>
<td>(174)</td>
<td>£368</td>
</tr>
<tr>
<td>Relocation Fund</td>
<td>£150</td>
<td>-</td>
<td>-</td>
<td>£150</td>
</tr>
<tr>
<td>Dilapidations</td>
<td>£277</td>
<td>£27</td>
<td>(205)</td>
<td>£99</td>
</tr>
<tr>
<td><strong>Total designated funds</strong></td>
<td>£969</td>
<td>£27</td>
<td>(379)</td>
<td>£617</td>
</tr>
<tr>
<td><strong>Total unrestricted funds</strong></td>
<td>£9,019</td>
<td>£12,134</td>
<td>(11,999)</td>
<td>£9,154</td>
</tr>
<tr>
<td><strong>Total funds</strong></td>
<td>£24,534</td>
<td>£30,579</td>
<td>(21,867)</td>
<td>£33,246</td>
</tr>
</tbody>
</table>
Prostate Cancer UK
Notes forming part of the financial statements
as at 31 March 2013

22 Purposes of restricted funds:

Movember Funds
Movember income from its campaigns, restricted to finance spending on research and survivorship services for men with prostate cancer in 2012/13 and beyond.

General research
Making awards to faculties for research that are not otherwise supported by organized or directed programmes.

Royal Mail
Funding for specialist/community nurses over a two year period to deliver first class care to men living with prostate cancer.

Marks & Spencer PLC
Funding for our specialist helpline to increase access and support for men and their families affected by prostate cancer.

Scotland Development - The Big Lottery Fund
Developing two services in West/Central Scotland:- one-to-one support for people directly affected by prostate cancer, and awareness raising of prostate cancer. Both services are run by people who have been directly affected by prostate cancer.

African Caribbean Projects
Staging of a community-based educational play, the production of a personal testimonies booklet collating experiences of people affected by prostate cancer and the production and distribution of a postcard aimed at raising awareness of prostate cancer amongst women.

Masterclasses
Supporting the running of nursing masterclasses.

Older and Wiser
Raising awareness in the African Caribbean community, including the training of volunteers in London.

National Cancer Survivorship Initiative
The final year of a three year grant funding specifically for survivorship of men with prostate cancer.

Statutory Income
To match fund a research programme provided by the Scottish Government which is restricted to Scotland.

23 Purposes of designated funds:
Designated funds are funds set aside from the general fund for objectives stated below:

Re-location fund
Costs to be incurred moving the London office.

Fixed asset reserves
Amount representing the net investment in fixed assets.

Dilapidations
Amount representing cost provisions for dilapidations on office leases.
24 Commitments under operating leases
At 31 March 2013, the charity had seven commitments under operating leases.

- Annual rent of £20,368 + VAT for the First floor 1-3 Worship Street London EC2A 2AB, lapsing on 3 November 2019.
- Annual rent of £7,237 + VAT for the Glasgow Office, with three months’ termination notice on either side.
- Annual rent of £7,812 + VAT for two additional units at the Glasgow Office, with three months’ termination notice on either side.
- Annual charge of £25,980 for photocopiers at the London office for 5 years from July 2008.
- Annual charge of £1,000 for one photocopier at the London office for 3 years from February 2011.
- Annual charge of £2,526 for one photocopier at the Glasgow office for 3 years from December 2010.

25 Note to group cash flow statement
Reconciliation of net movement in funds to net cash inflow from operating activities

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net movement in funds for year before other recognised gains or losses</td>
<td>8,712</td>
<td>12,879</td>
</tr>
<tr>
<td>Investment/Other Income</td>
<td>(135)</td>
<td>(91)</td>
</tr>
<tr>
<td>Depreciation</td>
<td>240</td>
<td>161</td>
</tr>
<tr>
<td>(Increase)/decrease in debtors</td>
<td>(2,035)</td>
<td>(13,119)</td>
</tr>
<tr>
<td>Increase/(decrease) in creditors</td>
<td>5,151</td>
<td>(2,019)</td>
</tr>
<tr>
<td></td>
<td><strong>11,933</strong></td>
<td><strong>(2,189)</strong></td>
</tr>
</tbody>
</table>

Analysis of net cash resources
Cash at bank and in hand | 2,812 | 2,821 |
Short term deposits       | 21,237 | 9,500 |
Cash at bank and in hand  | **24,049** | **12,321** |

At the end of March 2013, the charity held four fixed rate bonds of £2m each with Barclays Bank plc and Lloyds Bank plc. Two separate short term deposits of £3m each were held in sterling liquidity funds with Prime Rate Capital and BlackRock. A further short term deposit of £7.2 million was also held in liquidity funds with CCLA.

26 Related party transactions
The Council of Management is required to declare all outside interests. When any item arises where it may be considered a member has an interest it must be declared and the member concerned may not take part in that debate or any related decisions.
Prostate Cancer UK (formerly The Prostate Cancer Charity)

Legal and administrative details
Registered in England and Wales with the Charities Commission under charity number: 1005541
Registered in Scotland by the Office of the Scottish charity Regulator under charity number: SC039332
Registered company number: 02653887

Address
Prostate Cancer UK (formerly The Prostate Cancer Charity)
First floor
Cambridge House
100 Cambridge Grove
London W6 0LE

From 24 September 2013
Prostate Cancer UK
Fourth floor
The Counting House
53 Tooley Street
London SE1 2QN

Regional offices
Prostate Cancer UK (Scotland)
Unit F22-24
Festival Business Centre
150 Brand Street
Glasgow G51 1DH

Prostate Cancer UK (North East)
MEA House
Ellison Place
Newcastle upon Tyne
NE1 8XS

Prostate Cancer UK (North West)
Emerson Business Centre
11th Floor, Regent House
Heaton Lane
Stockport
SK4 1BS

Prostate Cancer UK (Midlands)
Studios 416-418
The Greenhouse
The Custard Factory
Gibb St, Birmingham
B9 4AA
Prostate Cancer UK (South East)
Units 13 and 14
2nd Floor
Green Dragon House
64-70 High Street
Croydon
CR0 9XN

Opening end of August 2013
Prostate Cancer UK (Wales)
Unit 1.8, The Maltings
East Tyndall Street
Cardiff CF24 5EZ

Bankers
National Westminster Bank Plc
Park Royal Branch
1 Abbey Road
London NW10 7RA

Auditors
MHA Macintyre Hudson
New Bridge Street House
30-34 New Bridge Street
London EC4V 6BJ

Legal Advisors
Russell-Cooke LLP
2 Putney Hill
London
SW15 6AB
Thank you

Our supporters have given their time, energy and commitment to our work and we are immensely grateful. A special mention in particular must go to the following:

Supporters (individuals)

- Thomas Dawber
- Michelle Dewbury
- Omid Djalili
- Craig Doyle
- Charlie Druce
- Rod Duval
- Professor Ros Eeles
- Bill Elliott
- Balthazar Fabricius
- Richard Farleigh
- Dennis Farmer
- Sir Ranulph Fiennes
- Les Ferdinand MBE
- Brian Foord
- Professor Chris Foster
- Mark Foster
- Wayne Francis
- Rebecca Front
- Stephen Fry
- David Funnell
- Jason Gardiner
- Tristan Gemmill
- Ricky Gervais
- Paul Godbold
- Adrian Goldsmith
- Mark Goodier
- Don Goodman
- Alastair Gordan
- David Graveney
- Rune Gustafson
- Dr Stephen Harland
- Mark Harold
- Bob Harris OBE
- Rachel Harris
- Angela Hartnett
- Wayne Hemingway MBE
- Dr Rob Hicks
- Steve Hindle
- Ken Hom OBE
- Sir Chris Hoy
- Stuart Hughes
- Colin Jackson CBE
- Felicity Jackson
- Matthew James
- Professor Nick James
- Boris Johnson
- Dr David Jones
- Edward Jones
- Frank Jones
- Alex Jones
- Dr Hilary Jones
- Diane Louise Jordan
- Adrian Joyce
- Diana Jupp
- Gary Kemp
- Andy Kingman
- Professor Mike Kirby
Thank you

Stuart Laing
Denis Law
Nigella Lawson
Laura Lee
Professor Nick Lemoine
Damian Lewis
Melissa Lewis
S Linnett
Dan Lobb
Fred MacAulay
Alan Macnair
Ian Marchant
Alan Marsh
Peter Martin
John Mason MSP
David Mason OBE
John Maxwell
Liam McArthur MSP
John McCririck
Debbie McGee
Sir Ian McKellen
Professor Stephanie McKeown
Alan McNair
Claudia McVie
Professor Killian Mellon
Philip Miller
Dr Ian Mills
Peter Moffat
Ugo Monye
David Moore
Paul Morgan
James Morley
Sir Stirling Moss
Professor Ken Muir
Al Murray
Sharmila Nebrhajani
Philip Nolan
Cyril Nri
Melvin Odoom
Tamzin Outhwaite
Colin Outhwaite
Mr and Mrs Gerry Pack
Dr Chris Parker
Gil Paterson MSP
Donald Peddie
Kazia Pelka
Katie Perry
Jess Phanwises
Bob Pow
Jo Pratt
Thane Prince
John Proctor
Dave Prowse
Jemma Redgrave
Harry Redknapp
Sir Tim Rice
Stefanie Ripley
Professor Craig Robson
Levi Roots
Stephen Rubin
Graham Russell
Martin Sadofski
Dominic Salmon
Bim Sandhu
Vernon Sankey
Tim Sargeant
David Schneider
Annie Scott
Tony Scutt
Angela Sharpe
Ben Shephard
Laurelle Simlett
John Simm
Peter Simpson
Hamish Slater
David Smith
Martin Smith
Jon Snow
Dan Snow
A Spicer
Rick Stein OBE
Jeff Stelling
Michael Stoute
Malcolm Strong
Neil Stuke
Mike Summerbee
Ellen Thomas
Sue Townsend
Martin Trainer
Joyce Underhill
Roger Uttley OBE
Tommy Walsh
Gok Wan
D Watts
Richard Watts
Samuel West
Mike Willgoss
Miranda Williams
Lord Wills
Ray Winstone
Anthony Woodburn
Oliver, Toby and Sophia Yates
Dwight Yorke
Benjamin Zephaniah

Prostate Cancer UK would also like to thank the many health professionals involved in its work over the past year. We look forward to working with you again in 2014.

A special thanks must also go to all of our Volunteers and Campaigners, whose passion and dedication to supporting Prostate Cancer UK is an inspiration to everyone involved with the charity.
Supporters (organisations)

Adnams Brewers
Airwave Europe Ltd
Alan Potter Golf Club
Alliance Healthcare Ltd
Anadur Foundation
Andor Charitable Trust
Barclays Bank plc
BP Chemicals Ltd Hull
Capital One (Europe) plc
Champneys Charitable Foundation
Childwick Trust
Donald Forrester Trust
Ecats Ltd
Finchley Golf Club
Garfield Weston Foundation
Greendale Charitable Foundation
Heineken UK
Iceland Foods Ltd
Janssen-Cilag Ltd
Juniper Training Ltd
Just Retirement Ltd
Keyline Builders Merchants
Kidan Memorial Trust
Magnolia Park Golf Club
Manor of Groves Golf Club
Marks & Spencer plc
Masonic Samaritan Fund
Missionfish
Pentel Stationery Ltd
Pirtek UK Ltd
Public Health Agency
Reuben Foundation
Robert Luff Foundation Limited
Robert McAlpine Foundation
Rochford Hundred Golf Club
Rotary Club of Goole
Royal Mail Group
Sir Samuel Scott of Yews Trust
Spirit Pub Company
The Austin & Hope Pilkington Trust
The Builders’ Conference
The Constance Travis Charitable Trust
The David Saunders Family Charitable Trust
The E C Graham Cumbrian Charitable Settlement
The Hargrave Foundation
The Headley Trust
The Henry Smith Charity
The Hoover Foundation
The John Beckwith Charitable Trust
The Joseph and Lena Randall Charitable Trust
The Mackintosh Foundation
The Mike Gooley Traffinders Charity
The Movember Foundation
The Philip King Charitable Trust
The Philip Oppenheimer Foundation
The Priory Foundation
The Simon Gibson Charitable Trust
The Sovereign Health Care Charitable Trust
The Swire Charitable Trust
Tom & Sheila Springer Charity

Pioneers

Thomas Allen
David Ashforth
John Stuart Bloor CBE
Vice President Lady Joy Bourne
Sir Adrian Cadbury
John Caudwell
Felix Dennis
Tony Elliot
Professor Mark Emberton
Baron Evans of Watford
Douglas Flint CBE
Alastair Gibbons
Sir Maurice Hatter
Sir Julian Horn-Smith
Nathan Kirsh
Stewart Matthewson
Brian Moss
New York Metz Foundation
Jim and Caroline O’Neill
John Paynter
David A Pretty CBE
Laurance Racke
Ivor Spiro
David Sullivan
Michael Tabor
The Cecil Rosen Foundation
The Stanley and Zea Lewis Family Foundation
Mr and Mrs John Tilney
Sir John Zochonis DL
We would like to thank our President, Vice Presidents, Trustees, Patrons, Ambassadors and supporters who served the charity during the year and thereafter, and continue to provide incredible support.

**President**

Professor Jonathan Waxman

**Vice Presidents**

Lady Joy Bourne
Anthony Kilmister OBE

**Trustees**

Dr Christopher Adams
John Anderson
Andrew Blessley
Dr Mark Britnell
Ian Chatte
Professor Paul Forster
Ray Kelly
Dr Hing Leung
David A Pretty CBE
Laurance Racke
Hugh Richardson
William Russell
Su Sayer
Christopher Smith
Vanessa Valely
Dr Timothy Walker

**President** Professor Jonathan Waxman

**Patrons**

Dame Mary Archer
The Rt Hon Tony Blair
Rabbi Lionel Blue OBE
The Rt Hon Gordon Brown MP
The Rt Hon Nick Clegg MP
Mike Gooley CBE
The Rt Hon Michael Howard QC MP
The Rt Hon Charles Kennedy MP
Lord Lloyd-Webber
The Rt Hon Sir John Major KG CH
The Rt Hon Sir Menzies Campbell, CBE, QC
Eminence Cardinal Cormac Murphy-O’Connor
The Rt Hon Baroness Pitkeathley OBE
The Chief Rabbi, Sir Jonathan Sacks
The Rt Hon the Lord Soley
The Rt Hon Iain Duncan Smith MP
The Rt Hon William Hague MP
The Most Reverend Archbishop Desmond Tutu

**Gift in Kind donors**

Racing Post
This is Global Ltd
Nestle UK
Prostate Cancer UK is such a worthy charity, that supports people, friends and families who may have been touched by this disease.

A personal experience
Donate today

Every year, 40,000 men face a prostate cancer diagnosis. Thanks to our generous supporters, we offer information free to all who need it. If you would like to help us continue this service, please consider making a donation. Your gift could fund the following services:

- £10 could buy a Tool Kit – a set of fact sheets, tailored to the needs of each man with vital information on diagnosis, treatment and lifestyle.
- £25 could give a man diagnosed with prostate cancer unlimited time to talk over treatment options with one of our specialist nurses.

To make a donation of any amount, please call us on 020 8222 7666, visit prostatecanceruk.org/donations or text PROSTATE to 70004*. There are many other ways to support us. For more details please visit prostatecanceruk.org/get-involved

*You can donate up to £10 via SMS and we will receive 100% of your donation. Texts are charged at your standard rate. For full terms and conditions and more information, please visit prostatecanceruk.org/terms
Supporting men
Finding answers
Leading change